Placebo‐controlled crossover assessment of mecasermin for the treatment of Rett syndrome. Issue 3 (31st January 2018)

• Record Type: Journal Article
• Authors: O'Leary, Heather M.; Kaufmann, Walter E.; Barnes, Katherine V.; Rakesh, Kshitiz; Kapur, Kush; Tarquinio, Daniel C.; Cantwell, Nicole G.; Roche, Katherine J.; Rose, Suzanne A.; Walco, Alexandra C.; Bruck, Natalie M.; Bazin, Grace A.; Holm, Ingrid A.; Alexander, Mark E.; Swanson, Lindsay C.; Baczewski, Lauren M.; Mayor Torres, Juan M.; Nelson, Charles A.; Sahin, Mustafa
• Is Part Of: Annals of clinical and translational neurology. Volume 5:Issue 3(2018)
• Page Start: 323
• Page End: 332
• Publication Date: 2018-01-31
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.533
• Languages: English
• ISSNs: 2328-9503

Abstract

Abstract: Objective: To measure the efficacy of mecasermin (recombinant human insulin‐like growth factor 1, rhIGF‐1), for treating symptoms of Rett syndrome (RTT) in a pediatric population using a double‐blind crossover study design. Methods: Thirty girls with classic RTT in postregression stage were randomly assigned to placebo or rhIGF‐1 in treatment period 1 and crossed over to the opposite assignment for period 2 (both 20 weeks), separated by a 28‐week washout period. The primary endpoints were as follows: Anxiety Depression and Mood Scale (ADAMS) Social Avoidance subscale, Rett Syndrome Behaviour Questionnaire (RSBQ) Fear/Anxiety subscale, Parent Target Symptom Visual Analog Scale (PTSVAS) top three concerns, Clinical Global Impression (CGI), Parent Global Impression (PGI), and the Kerr severity scale. Cardiorespiratory‐ and electroencephalography (EEG)‐based biomarkers were also analyzed. Results: There were no significant differences between randomization groups. The majority of AEs were mild to moderate, although 12 episodes of serious AEs occurred. The Kerr severity scale, ADAMS Depressed Mood subscale, Visual Analog Scale Hyperventilation, and delta average power change scores significantly increased, implying worsening of symptoms. Electroencephalography (EEG) parameters also deteriorated. A secondary analysis of subjects who were not involved in a placebo recall confirmed most of these findings. However, it also revealed improvements on a measure of stereotypic behavior and another of social communication. Interpretation: As in the phase 1 trial, rhIGF‐1 was safe; however, the drug did not reveal significant improvement, and some parameters worsened.